Insights into the potential of Sanguinarine as a promising therapeutic option for breast cancer

被引:6
|
作者
Malla, Rama Rao [1 ]
Bhamidipati, Priyamvada [1 ]
Adem, Meghapriya [2 ]
机构
[1] GITAM Deemed Univ, Sch Sci, Dept Biochem & Bioinformat, Canc Biol Lab, Visakhapatnam 530045, Andhra Prades, India
[2] Sri Padmavathi Mahila Visva vidhyalayam, Dept Biotechnol, Tirupati 517502, Andhra Prades, India
关键词
Breast cancer; Hypoxia; Prognosis; Sanguinarine; Tumor microenvironment; INDUCED APOPTOSIS; LUNG-CANCER; OXIDATIVE STRESS; OVARIAN-CANCER; CELL-DEATH; EXPRESSION; ACTIVATION; MDA-MB-231; INHIBITOR; MECHANISM;
D O I
10.1016/j.bcp.2023.115565
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer (BC) is one of the leading causes of cancer-related deaths in women worldwide. The tumor microenvironment (TME) plays a crucial role in the progression and metastasis of BC. A significant proportion of BC is characterized by a hypoxic TME, which contributes to the development of drug resistance and cancer recurrence. Sanguinarine (SAN), an isoquinoline alkaloid found in Papaver plants, has shown promise as an anticancer agent. The present review focuses on exploring the molecular mechanisms of hypoxic TME in BC and the potential of SAN as a therapeutic option. The review presents the current understanding of the hypoxic TME, its signaling pathways, and its impact on the progression of BC. Additionally, the review elaborates on the mechanisms of action of SAN in BC, including its effects on vital cellular processes such as proliferation, migration, drug resistance, and tumor-induced immune suppression. The review highlights the importance of addressing hypoxic TME in treating BC and the potential of SAN as a promising therapeutic option.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Cytokine blockade - a promising therapeutic option in SLE
    Aringer, M.
    Feierl, E.
    Smolen, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2008, 67 (04): : 315 - 317
  • [32] Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond
    Wesierska-Gadek, Jozefa
    Mauritz, Matthias
    FUTURE MEDICINAL CHEMISTRY, 2016, 8 (01) : 55 - 72
  • [33] EphA2: A promising therapeutic target in breast cancer
    Ping Zhao
    Dewei Jiang
    Yunchao Huang
    Ceshi Chen
    Journal of Genetics and Genomics, 2021, 48 (04) : 261 - 267
  • [34] Skp2 is a promising therapeutic target in breast cancer
    Wang, Zhiwei
    Fukushima, Hidefumi
    Inuzuka, Hiroyuki
    Wan, Lixin
    Liu, Pengda
    Gao, Daming
    Sarkar, Fazlul H.
    Wei, Wenyi
    FRONTIERS IN ONCOLOGY, 2012, 1
  • [35] EphA2: A promising therapeutic target in breast cancer
    Zhao, Ping
    Jiang, Dewei
    Huang, Yunchao
    Chen, Ceshi
    JOURNAL OF GENETICS AND GENOMICS, 2021, 48 (04) : 261 - 267
  • [36] MMK4 is a promising therapeutic target for breast cancer
    Meng-Lay, Lin
    Katagiri, Toyomasa
    Nishidate, Toshihiko
    Nakatsuru, Shuichi
    Nakamura, Yusuke
    CANCER RESEARCH, 2006, 66 (08)
  • [37] Promising therapeutic options in triple-negative breast cancer
    Bilici, A.
    Arslan, C.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (02): : 209 - 222
  • [38] Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications
    Sher, Gulab
    Salman, Nadia Aziz
    Khan, Abdul Q.
    Prabhu, Kirti S.
    Raza, Afsheen
    Kulinski, Michal
    Dermime, Said
    Haris, Mohammad
    Junejo, Kulsoom
    Uddin, Shahab
    SEMINARS IN CANCER BIOLOGY, 2022, 83 : 152 - 165
  • [39] PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives
    Qi, Yalong
    Li, Lixi
    Wei, Yuhan
    Ma, Fei
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [40] Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
    Barkat, Md Abul
    Harshita
    Ahmad, Javed
    Khan, Mohammad Ahmed
    Beg, Sarwar
    Ahmad, Farhan Jalees
    CURRENT DRUG TARGETS, 2018, 19 (01) : 70 - 80